Questions this desk gets, answered from the record

What is CJC-1295?

CJC-1295 is a synthetic analog of growth-hormone-releasing hormone built on hGRF(1-29), the first 29 residues of the native 44-residue hormone. It carries four amino-acid substitutions — D-alanine at 2, glutamine at 8, alanine at 15, leucine at 27 — that stabilise the helix and block cleavage by dipeptidyl peptidase IV, and in the DAC variant a maleimidopropionyl linker bonds it covalently to circulating serum albumin, extending its clearance toward that of albumin itself ^[7]. It has no approved human indication anywhere and is sold for laboratory research use only. It is prohibited in sport at all times, and it has been structurally identified by LC-MS/MS as the active ingredient of an unlabelled preparation seized in an anti-doping context ^[2].

What does CJC-1295 do?

It binds the GHRH receptor on anterior-pituitary somatotrophs and drives Gs/cAMP/PKA signalling, increasing synthesis and pulsatile release of growth hormone, with hepatic IGF-1 rising downstream. In healthy adults, single subcutaneous doses of 30 or 60 micrograms per kilogram produced dose-dependent 2- to 10-fold increases in mean plasma GH for six days or more and 1.5- to 3-fold increases in IGF-1 for nine to eleven days, with an estimated half-life of 5.8 to 8.1 days ^[4]. The mechanistically important result is what it does not do: in healthy men aged 20 to 40, a single dose raised trough GH roughly 7.5-fold and mean GH and IGF-1 by about 46% and 45% a week later while leaving the frequency and magnitude of pulsatile secretion unaltered ^[5]. Continuous stimulation at the receptor did not flatten the pulse.

How much CJC-1295 should I take?

No figure appears on this site in answer to that question, and the reason is not caution for its own sake. There is no human dosing standard for CJC-1295, because there is no approved indication and no clinical programme that established one — the published human data are early pharmacology studies in volunteers, not dose-finding for any outcome ^[4][5].

What the literature does contain is the exposures those studies used, reported here as descriptions of experiments: 30 or 60 micrograms per kilogram as single subcutaneous doses in one ^[4], 60 or 90 micrograms per kilogram in another ^[5]. Those were administered under study conditions to measure GH and IGF-1 kinetics. They are not a recommendation, they are not scaled to any individual, and this desk does not convert them into one.

Most dosing protocols circulating online are not derived from controlled human trials at all. A further problem sits underneath the question: the DAC and no-DAC forms differ in duration by orders of magnitude ^[4][7], so any exposure figure that does not name the form describes nothing.

Is CJC-1295 safe?

Long-term safety in humans is unknown. The published human record consists of small pharmacokinetic studies that were not designed as safety assessments ^[4][5], and no large or long-duration trial exists in healthy adults. The concerns documented in the literature are: theoretical oncologic risk from sustained IGF-1 elevation, since IGF-1 is mitogenic and epidemiologic work associates higher circulating IGF-1 with modestly increased risk of certain cancers; fluid retention, edema and nerve-compression symptoms driven by GH-mediated sodium and water retention; reduced insulin sensitivity, since GH is glucose-sparing; and immunogenicity, which FDA briefing materials for the 2024 Pharmacy Compounding Advisory Committee cited among the grounds for not recommending it for the Section 503A bulks list. Separately, the original long-acting development programme was discontinued and a patient death from that era is frequently cited alongside the halted Phase 2 trial; the public record does not establish causation, and the accurate reading is unresolved history rather than proof of harm.

What is ipamorelin peptide?

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from GHRP-1 by removal of the central Ala-Trp dipeptide. It is a selective agonist of the ghrelin / growth-hormone-secretagogue receptor GHS-R1a — which is the point of it. It releases growth hormone through a receptor entirely different from the one GHRH analogs use, and it does so without meaningfully raising ACTH, cortisol or prolactin, unlike the earlier growth-hormone-releasing peptides GHRP-6 and GHRP-2. It has never been approved as a drug anywhere; in 2024 it was removed from Category 2 of the FDA's interim Section 503A bulk substances list and reviewed at the October 2024 Pharmacy Compounding Advisory Committee meeting.

What are the risks of ipamorelin?

The evidence gaps come first, because they frame everything else: the entire controlled human record is one Phase 2 trial of up to seven days of intravenous dosing in 114 patients ^[10] and one acute single-dose infusion study ^[11]. There is no Phase 3, no long-term safety database, and no published safety or pharmacokinetic characterisation of the subcutaneous route that dominates real-world use.

The mechanism-based concerns are: proliferative risk from GH-driven IGF-1 elevation, class-level and unresolved for this compound specifically; unpredictable glycaemic effects, because GH reduces insulin sensitivity while ipamorelin separately shows a direct insulin-releasing action on pancreatic islet tissue ex vivo; appetite and adiposity effects, since GHS-R1a agonism activates hypothalamic feeding circuitry and ipamorelin has shown GH-independent stimulation of adiposity in mice; and a cardiovascular signal at the class level — a 28-day study of a structurally distinct GHS-R1a agonist produced dose-dependent myocardial degeneration and necrosis in rats, with elevated heart-type fatty-acid-binding protein but no rise in serum cardiac troponin ^[9]. Ipamorelin itself was not the tested compound, and no equivalent long-duration cardiovascular study of it exists in any species. Research-grade supply adds unverified identity, purity and sterility on top.

What is sermorelin?

Sermorelin acetate is an amidated synthetic 29-amino-acid peptide identical to the amino-terminal 1-29 fragment of endogenous human growth-hormone-releasing hormone — the shortest fragment that retains full activity at the GHRH receptor ^[1]. It binds GHRH receptors on pituitary somatotrophs and activates the adenylate cyclase / cAMP / PKA pathway, stimulating the body's own pulsatile growth-hormone release rather than supplying growth hormone from outside, so somatostatin and IGF-1 feedback remain intact. It held a US approval for pediatric growth-hormone deficiency and short stature, withdrawn from the market in 2008 for commercial reasons rather than for safety or efficacy, and it is now handled through compounding pharmacies as a Category 1 bulk drug substance under the FDA's interim Section 503A policy.

Does sermorelin work?

It depends entirely on which claim is being tested, and the two are usually merged.

In prepubertal growth-hormone-deficient children, once-daily subcutaneous GHRH(1-29) accelerated linear growth in a multicentre trial, with first-year height velocity rising from about 4.1 centimetres per year to roughly 7 to 8 centimetres per year, and without excessive IGF-1 generation ^[16]. That is a positive controlled result for a deficiency indication.

For adult anti-aging, body composition and vitality — the uses it is actually marketed for — the rigorous long-term data do not exist. The randomised evidence most often cited in support belongs to a different molecule: a trial of tesamorelin (Egrifta) in 152 older adults, 66 with mild cognitive impairment, which reported a favourable cognitive effect (P = 0.03), a 117% rise in IGF-1 within the physiologic range, and a 7.4% reduction in percent body fat over 20 weeks ^[13]. That supports the GHRH-analog class, not sermorelin specifically. An Annals of Internal Medicine editorial concluded that using growth-hormone secretagogues to prevent or treat the effects of aging is not yet justified by the evidence — "not yet ready for prime time" ^[14] — and nothing catalogued here has overturned it.

How long does it take for sermorelin to work?

Two different clocks get confused in this question. Pharmacologically the effect is immediate: sermorelin binds GHRH receptors and stimulates a growth-hormone pulse within the same session, which is why it is studied as an intermittent signal and why continuous exposure is counterproductive — given as a non-stop infusion in children, the growth-hormone response faded after a few months and one child's secretion was fully suppressed.

The clock people usually mean is the one for perceived change, and there the only material available is community report. This is anecdotal, not clinical evidence: research-use and telehealth communities describe sermorelin as a slow burn, with the first month often feeling like nothing, sleep and energy changes appearing in the second or third month, and body-composition change described over a longer span still. Several accounts describe early disappointment. Reported outcomes vary widely and are confounded by sleep, diet and training. In controlled work, the measured endpoint that has a timeline attached is growth velocity over a first year of treatment in children ^[16].

What does the MOTS-c peptide do?

MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. Its best-characterised action is inhibition of the folate cycle and de novo purine biosynthesis, which raises AICAR and activates AMPK, improving glucose handling and insulin sensitivity primarily in skeletal muscle ^[19]. Under metabolic stress it translocates from the mitochondrion to the nucleus and regulates nuclear gene expression in an AMPK-dependent manner, including antioxidant-response-element genes through NRF2 — the first demonstrated retrograde signalling by a mitochondrially encoded peptide ^[21]. A 2024 study identified casein kinase 2 as a directly bound and activated target, with tissue-specific modulation underlying effects on muscle glucose uptake and atrophy prevention ^[17]. Exercise induces the endogenous peptide, and administered MOTS-c enhanced physical performance in young, middle-aged and old mice ^[20]. What it does not do is act on the pituitary, growth hormone or IGF-1.

How often do you inject MOTS-c?

This desk publishes no schedule for MOTS-c, and in this case the reason is unusually concrete rather than merely cautious: there is no published, measured human half-life, bioavailability or dose-response for the compound. Without human pharmacokinetics there is no interval to describe, and rodent work uses milligram-per-kilogram exposures that cannot be extrapolated to people.

No human efficacy trial of exogenous MOTS-c has been conducted for any indication. Every performance and metabolic claim traces to cell or animal studies ^[17][19][20], and the strongest human data measure the body's own circulating peptide as a biomarker — in a cohort of 94 chronic haemodialysis patients, endogenous MOTS-c was independently associated with mortality and cardiovascular events and improved risk-model discrimination ^[18]. That is an observation about a biomarker, not a finding about administering anything. Any interval circulating online is invention, not extrapolation from a published human study.

What is the difference between a GHRH analog and a ghrelin-receptor agonist?

They are two different receptors on the same pituitary cell, reaching the same output by unrelated routes — the distinction this whole site is organised around.

A GHRH analog such as sermorelin or CJC-1295 binds GHRHR, the receptor the hypothalamus's own signal uses, and activates the Gs/cAMP/PKA cascade ^[1][7]. Because it enters the axis where the endogenous signal enters it, somatostatin tone and IGF-1 feedback continue to shape the output; that is why a GHRH analog raises pulse height rather than producing a plateau, a result measured directly for CJC-1295 ^[5].

A ghrelin-receptor agonist such as ipamorelin binds GHS-R1a, the receptor for the stomach-derived hormone ghrelin, and reaches the secretory machinery by a different intracellular route. Its GH effect is one short discrete pulse — a terminal half-life of roughly 2 hours with the response peaking about 40 minutes after administration ^[11]. GHS-R1a is also expressed on enteric and vagal neurons, pancreatic islets and hypothalamic appetite circuitry, which is why appetite belongs to this mechanism and not to the GHRH one.

Because the receptors are separate, the two mechanisms are complementary rather than redundant, which is the pharmacological argument for pairing them. The argument stops at pharmacology: no controlled trial of the combination against an outcome has been published ^[10].